Media stories about Argos Therapeutics (NASDAQ:ARGS) have trended somewhat positive on Tuesday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Argos Therapeutics earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 47.4687848676899 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
NASDAQ ARGS traded down $0.03 on Tuesday, hitting $1.11. 602,644 shares of the stock were exchanged, compared to its average volume of 786,475. The company has a current ratio of 1.80, a quick ratio of 1.80 and a debt-to-equity ratio of -1.31. Argos Therapeutics has a fifty-two week low of $0.70 and a fifty-two week high of $16.40.
Separately, ValuEngine upgraded shares of Argos Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.
Argos Therapeutics, Inc, an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer.
Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.